Expression and activity of prolactin receptor isoforms in non-malignant and malignant lung cells

Background In recent years, the involvement of prolactin (PRL) in different malignancies, such as breast and prostate cancer, has been reported. Recently, prolactin was also proposed as a biomarker for lung cancer, but its molecular mechanisms remain to be explored in this tissue. The aim of this work was to assess the expression of the prolactin receptor (PRLR) and its isoforms, using non-tumorigenic bronchial epithelial (BEAS-2B) cells as a non-malignant model, and A549 and SK-LU-1 cell lines derived from lung adenocarcinoma (LUAD) as a malignant model. Moreover, the STAT5 signaling pathway was analyzed after the administration of PRL, along with its effects on cell viability in these lung cancer cell lines.Methods PRLR expression was assessed by Western blot, RT-PCR, and immunofluorescence, while STAT5 activation was evaluated via Western blot for p-STAT5 detection and immunofluorescence for nuclear translocation. Additionally, cell viability was determined using the MTT assay.Results We found differential expression of PRLR isoforms at both the mRNA and protein levels. PRLR protein expression was differentially localized in the subcellular compartments of the A549 and SK-LU-1 LUAD cell lines. Furthermore, even at low doses of PRL treatment, an increase in p-STAT5 (a marker of PRLR canonical pathway) and its subsequent translocation to the nucleus were observed in the SK-LU-1 cell line, indicating the activation of this pathway by PRL. Furthermore, we did not observe significant differences in cell viability after PRL administration at low doses; however, treatment with higher doses of PRL increased the cell viability in SK-LU-1 cells at 24 h and in BEAS-2B cells at 72 h.Conclusions Overall, the results indicate that isoforms of PRLR are expressed in non-tumorigenic and LUAD cells, and that PRL treatment induces STAT5 translocation, suggesting that its effects may be mediated by different PRLR isoforms. However, further studies involving other types of lung cell lines are needed to determine their role in lung pathophysiology.

Authors

Institutions

Publication Details

Journal
Molecular & Cellular Oncology
Published
2026-11-13
DOI
https://doi.org/10.1080/23723556.2026.2742590
Primary Topic
Growth Hormone and Insulin-like Growth Factors
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Expression and activity of prolactin receptor isoforms in non-malignant and malignant lung cells

Édgar Vergara, Luis Daniel Martínez‐Razo, Ignacio González‐Sánchez, Ericka K. P. Almeida-Aguirre et al.
Molecular & Cellular Oncology
Growth Hormone and Insulin-like Growth Factors
article

Expression and activity of prolactin receptor isoforms in non-malignant and malignant lung cells

Édgar Vergara, Luis Daniel Martínez‐Razo, Ignacio González‐Sánchez, Ericka K. P. Almeida-Aguirre, Vianey Rodríguez-Lara, Marco Cerbón, Anaiza Rico-Luna
article en

Abstract

Background In recent years, the involvement of prolactin (PRL) in different malignancies, such as breast and prostate cancer, has been reported. Recently, prolactin was also proposed as a biomarker for lung cancer, but its molecular mechanisms remain to be explored in this tissue. The aim of this work was to assess the expression of the prolactin receptor (PRLR) and its isoforms, using non-tumorigenic bronchial epithelial (BEAS-2B) cells as a non-malignant model, and A549 and SK-LU-1 cell lines derived from lung adenocarcinoma (LUAD) as a malignant model. Moreover, the STAT5 signaling pathway was analyzed after the administration of PRL, along with its effects on cell viability in these lung cancer cell lines.Methods PRLR expression was assessed by Western blot, RT-PCR, and immunofluorescence, while STAT5 activation was evaluated via Western blot for p-STAT5 detection and immunofluorescence for nuclear translocation. Additionally, cell viability was determined using the MTT assay.Results We found differential expression of PRLR isoforms at both the mRNA and protein levels. PRLR protein expression was differentially localized in the subcellular compartments of the A549 and SK-LU-1 LUAD cell lines. Furthermore, even at low doses of PRL treatment, an increase in p-STAT5 (a marker of PRLR canonical pathway) and its subsequent translocation to the nucleus were observed in the SK-LU-1 cell line, indicating the activation of this pathway by PRL. Furthermore, we did not observe significant differences in cell viability after PRL administration at low doses; however, treatment with higher doses of PRL increased the cell viability in SK-LU-1 cells at 24 h and in BEAS-2B cells at 72 h.Conclusions Overall, the results indicate that isoforms of PRLR are expressed in non-tumorigenic and LUAD cells, and that PRL treatment induces STAT5 translocation, suggesting that its effects may be mediated by different PRLR isoforms. However, further studies involving other types of lung cell lines are needed to determine their role in lung pathophysiology.

Molecular & Cellular OncologyVol. 13(1)
Hospital General de México (MX), Hospital General Dr. Manuel Gea Gonzalez (MX), Universidad Nacional Autónoma de México (MX)
Universidad Nacional Autónoma de México, Dirección General de Asuntos del Personal Académico, Universidad Nacional Autónoma de México
Good health and well-being
Growth Hormone and Insulin-like Growth Factors
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon